M6AREG: M6A-centered Regulation of Disease Development and Drug Response

Overview

Journal Nucleic Acids Res

Publisher Oxford University Press

Specialty Biochemistry

Date 2022 Sep 22

PMID 36134713

Authors

Shuiping Liu

Lu Chen

Yintao Zhang

Ying Zhou

Ying He

Zhen Chen

Shasha Qi

Jinyu Zhu

Xudong Chen

Hao Zhang

Yongchao Luo

Yunqing Qiu

Lin Tao

Feng Zhu

Affiliations

Soon will be listed here.

Abstract

As the most prevalent internal modification in eukaryotic RNAs, N6-methyladenosine (m6A) has been discovered to play an essential role in cellular proliferation, metabolic homeostasis, embryonic development, etc. With the rapid accumulation of research interest in m6A, its crucial roles in the regulations of disease development and drug response are gaining more and more attention. Thus, a database offering such valuable data on m6A-centered regulation is greatly needed; however, no such database is as yet available. Herein, a new database named 'M6AREG' is developed to (i) systematically cover, for the first time, data on the effects of m6A-centered regulation on both disease development and drug response, (ii) explicitly describe the molecular mechanism underlying each type of regulation and (iii) fully reference the collected data by cross-linking to existing databases. Since the accumulated data are valuable for researchers in diverse disciplines (such as pathology and pathophysiology, clinical laboratory diagnostics, medicinal biochemistry and drug design), M6AREG is expected to have many implications for the future conduct of m6A-based regulation studies. It is currently accessible by all users at: https://idrblab.org/m6areg/.

Citing Articles

TDP-43/ALKBH5-mediated mA modification of CDC25A mRNA promotes glioblastoma growth by facilitating G1/S cell cycle transition.

Zhang Y, Xie S, Li W, Gu J, Zhang X, Ni B MedComm (2020). 2025; 6(3):e70108.

PMID: 39974663 PMC: 11836349. DOI: 10.1002/mco2.70108.

Multichrome encoding-based multiplexed, spatially resolved imaging reveals single-cell RNA epigenetic modifications heterogeneity.

Mao D, Tang X, Zhang R, Hu S, Gou H, Zhang P Nat Commun. 2025; 16(1):958.

PMID: 39843433 PMC: 11754832. DOI: 10.1038/s41467-025-56331-w.

The role of artificial intelligence in drug screening, drug design, and clinical trials.

Wu Y, Ma L, Li X, Yang J, Rao X, Hu Y Front Pharmacol. 2024; 15:1459954.

PMID: 39679365 PMC: 11637864. DOI: 10.3389/fphar.2024.1459954.

Statistical modeling of single-cell epitranscriptomics enabled trajectory and regulatory inference of RNA methylation.

Wang H, Wang Y, Zhou J, Song B, Tu G, Nguyen A Cell Genom. 2024; 5(1):100702.

PMID: 39642887 PMC: 11770222. DOI: 10.1016/j.xgen.2024.100702.

The role and mechanism of "eight famous herbals in Zhejiang" in cancer via network pharmacology and experimental validation.

Ni Z, Zhang H, Chen F, Yang M, Yang L, Zhou Y Front Oncol. 2024; 14:1475000.

PMID: 39628999 PMC: 11612504. DOI: 10.3389/fonc.2024.1475000.

References

Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millan-Zambrano G, Robson S . Promoter-bound METTL3 maintains myeloid leukaemia by mA-dependent translation control. Nature. 2017; 552(7683):126-131. PMC: 6217924. DOI: 10.1038/nature24678. View

Chien C, Li J, Chien Y, Wang M, Yarmishyn A, Tsai P . METTL3-dependent N-methyladenosine RNA modification mediates the atherogenic inflammatory cascades in vascular endothelium. Proc Natl Acad Sci U S A. 2021; 118(7). PMC: 7896299. DOI: 10.1073/pnas.2025070118. View

Lan Q, Liu P, Bell J, Wang J, Huttelmaier S, Zhang X . The Emerging Roles of RNA mA Methylation and Demethylation as Critical Regulators of Tumorigenesis, Drug Sensitivity, and Resistance. Cancer Res. 2021; 81(13):3431-3440. DOI: 10.1158/0008-5472.CAN-20-4107. View

Gu Y, Niu S, Wang Y, Duan L, Pan Y, Tong Z . -Mediated Regulation of mA-Modified by mA Reader IGF2BP3 Drives ccRCC Progression. Cancer Res. 2020; 81(4):923-934. DOI: 10.1158/0008-5472.CAN-20-1619. View

Yin J, Li F, Zhou Y, Mou M, Lu Y, Chen K . INTEDE: interactome of drug-metabolizing enzymes. Nucleic Acids Res. 2020; 49(D1):D1233-D1243. PMC: 7779056. DOI: 10.1093/nar/gkaa755. View

Xuan J, Sun W, Lin P, Zhou K, Liu S, Zheng L . RMBase v2.0: deciphering the map of RNA modifications from epitranscriptome sequencing data. Nucleic Acids Res. 2017; 46(D1):D327-D334. PMC: 5753293. DOI: 10.1093/nar/gkx934. View

De Jesus D, Zhang Z, Kahraman S, Brown N, Chen M, Hu J . mA mRNA Methylation Regulates Human β-Cell Biology in Physiological States and in Type 2 Diabetes. Nat Metab. 2019; 1(8):765-774. PMC: 6924515. DOI: 10.1038/s42255-019-0089-9. View

Zeng C, Huang W, Li Y, Weng H . Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020; 13(1):117. PMC: 7457244. DOI: 10.1186/s13045-020-00951-w. View

Zhang S, Sun X, Mou M, Amahong K, Sun H, Zhang W . REGLIV: Molecular regulation data of diverse living systems facilitating current multiomics research. Comput Biol Med. 2022; 148:105825. DOI: 10.1016/j.compbiomed.2022.105825. View

10.

Nombela P, Miguel-Lopez B, Blanco S . The role of mA, mC and Ψ RNA modifications in cancer: Novel therapeutic opportunities. Mol Cancer. 2021; 20(1):18. PMC: 7812662. DOI: 10.1186/s12943-020-01263-w. View

11.

Huang H, Weng H, Chen J . mA Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell. 2020; 37(3):270-288. PMC: 7141420. DOI: 10.1016/j.ccell.2020.02.004. View

12.

Dixit D, Prager B, Gimple R, Poh H, Wang Y, Wu Q . The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discov. 2020; 11(2):480-499. PMC: 8110214. DOI: 10.1158/2159-8290.CD-20-0331. View

13.

The Lancet . ICD-11: a brave attempt at classifying a new world. Lancet. 2018; 391(10139):2476. DOI: 10.1016/S0140-6736(18)31370-9. View

14.

Chen K, Song B, Tang Y, Wei Z, Xu Q, Su J . RMDisease: a database of genetic variants that affect RNA modifications, with implications for epitranscriptome pathogenesis. Nucleic Acids Res. 2020; 49(D1):D1396-D1404. PMC: 7778951. DOI: 10.1093/nar/gkaa790. View

15.

Wang X, Li F, Qiu W, Xu B, Li Y, Lian X . SYNBIP: synthetic binding proteins for research, diagnosis and therapy. Nucleic Acids Res. 2021; 50(D1):D560-D570. PMC: 8728148. DOI: 10.1093/nar/gkab926. View

16.

Qu X, Zhang Y, Sang X, Ren D, Zhao H, Wong S . Methyladenosine Modification in RNAs: From Regulatory Roles to Therapeutic Implications in Cancer. Cancers (Basel). 2022; 14(13). PMC: 9264946. DOI: 10.3390/cancers14133195. View

17.

Deng S, Zhang H, Zhu K, Li X, Ye Y, Li R . M6A2Target: a comprehensive database for targets of m6A writers, erasers and readers. Brief Bioinform. 2020; 22(3). DOI: 10.1093/bib/bbaa055. View

18.

Liu H, Wang H, Wei Z, Zhang S, Hua G, Zhang S . MeT-DB V2.0: elucidating context-specific functions of N6-methyl-adenosine methyltranscriptome. Nucleic Acids Res. 2017; 46(D1):D281-D287. PMC: 5753212. DOI: 10.1093/nar/gkx1080. View

19.

Yang S, Wei J, Cui Y, Park G, Shah P, Deng Y . mA mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019; 10(1):2782. PMC: 6592937. DOI: 10.1038/s41467-019-10669-0. View

20.

Liu S, Li Q, Chen K, Zhang Q, Li G, Zhuo L . The emerging molecular mechanism of mA modulators in tumorigenesis and cancer progression. Biomed Pharmacother. 2020; 127:110098. DOI: 10.1016/j.biopha.2020.110098. View